- Home
- NRIM vs PACB Comparison
NRIM vs PACB Comparison
Compare NRIM & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | PACB |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 555.5M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NRIM | PACB |
|---|---|---|
| Price | $24.11 | $2.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 173.4K | ★ 8.0M |
| Earning Date | 01-23-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 73.41 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $208,902,000.00 | $154,584,000.00 |
| Revenue This Year | N/A | $4.19 |
| Revenue Next Year | $15.38 | $12.04 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 37.50 | N/A |
| 52 Week Low | $16.18 | $0.85 |
| 52 Week High | $30.82 | $2.73 |
Technical Indicators
Market Signals| Indicator | NRIM | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 62.17 |
| Support Level | $28.22 | $2.09 |
| Resistance Level | $30.82 | $2.73 |
| Average True Range (ATR) | 1.17 | 0.20 |
| MACD | -0.38 | 0.06 |
| Stochastic Oscillator | 7.88 | 76.40 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.